Ann: Change in substantial holding, page-18

Yes I don't expect "smart money" to come into this without some reasonable backing on the sales of Febridx and Viradx in the US, however, if there is a clear understanding as to why the product isn't taking off in other countries then you cant correlate both regions. The "rest of world" outside the US dont have the reimbursement of product structure that the US has, so uptake of the product is going to be much more difficult than in the US.The core product sales in the rest of world regions sold $300K worth of product last financial year inclusive of Febridx and reader sales. $1.7M reduction due to Covidx sales drop. People really need to exclude the black swan of Covid as it skews all sorts of metrics. From the annual, there was $200K reduction in sales of product including Febridx, Viradx and readers excluding Covidx reduction.If the quarterly which now includes US sales is greater than $300K then its a massive positive (in addition to HS services revenue). I would say anything above $500K in product sales for the quarter would be huge for upside on growth given Covidx is not in market anymore.